NCT01831076View on ClinicalTrials.gov

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

February 28, 2013

Study Completion Date

January 6, 2022

Conditions
Breast CancerStage II Breast CancerStage III Breast Cancer
Interventions
DRUG

Exemestane

Given PO

DRUG

Exemestane and tamoxifen

exemestane 25 mg po daily and tamoxifen 20 mg po daily given concurrently for 4 months prior to surgery

Trial Locations (1)

80045

University of Colorado Cancer Center, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT01831076 - Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors | Biotech Hunter | Biotech Hunter